LEADER 03782oam 2200685I 450 001 9910806250903321 005 20230803202142.0 010 $a0-429-16933-7 010 $a1-4665-9387-3 024 7 $a10.1201/b16749 035 $a(CKB)3710000000099004 035 $a(EBL)1408064 035 $a(SSID)ssj0001181236 035 $a(PQKBManifestationID)11639740 035 $a(PQKBTitleCode)TC0001181236 035 $a(PQKBWorkID)11143189 035 $a(PQKB)11074665 035 $a(OCoLC)880460508 035 $a(MiAaPQ)EBC1408064 035 $a(OCoLC)876288586 035 $a(EXLCZ)993710000000099004 100 $a20180331h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aClinical and statistical considerations in personalized medicine /$fedited by Claudio Carini, Pfizer, Cambridge, Massachusetts, USA, Sandeep M. Menon, Pfizer, Cambridge, Massachusetts, USA, Mark Chang, AMAG Pharmaceuticals, Incorporated Waltham, Massach 210 1$aBoca Raton :$cCRC Press,$d[2014] 210 4$dİ2014 215 $a1 online resource (368 p.) 225 1 $aChapman and Hall/CRC Biostatistics Series 300 $aDescription based upon print version of record. 311 $a1-306-86777-0 311 $a1-4665-9386-5 320 $aIncludes bibliographical references. 327 $aFront Cover; Contents; Preface; Editors; Contributors; Chapter 1: Biomarkers for Drug Development: The Time Is Now!; Chapter 2: RNAi Screens: Triumphs and Tribulations; Chapter 3: Current Advances in Epigenetics; Chapter 4: Biomarkers and Precision Medicine: The Case of Rare Diseases; Chapter 5: Biomarker-Informed Adaptive Design; Chapter 6: Fitting the Dose: Adaptive Staggered Dose Design; Chapter 7: Evidence-Based Adaptive Statistical Decision and Design Strategies for; Chapter 8: Biomarker Identification in Clinical Trials; Chapter 9: Multiplicity in Pharmacogenomics 327 $aChapter 10: Patient-Reported Outcomes in Personalized MedicineChapter 11: Regulatory Issues in Use of Biomarkers in Drug Development; Back Cover 330 $aPersonalized medicine has the potential to change the way we think about, identify, and manage health problems. In the pharmaceutical industry, it is already having an exciting impact on both clinical research and patient care. This impact will continue to grow as our understanding and technologies improve. With contributions from well-known industry leaders in clinical development, this book covers the practical aspects of personalized medicine, focusing on issues that have direct application in the industry. Topics include designs for targeted therapy, adaptive designs, evidence-based adaptive statistical decisions, and design strategies for maximizing the efficiency of clinical oncology--$cProvided by publisher. 410 0$aChapman & Hall/CRC biostatistics series (Unnumbered) 606 $aPharmacogenetics$xMathematical models 606 $aPharmacogenetics$xStatistical methods 606 $aPharmacogenomics$xMathematical models 606 $aPharmacogenomics$xStatistical methods 615 0$aPharmacogenetics$xMathematical models. 615 0$aPharmacogenetics$xStatistical methods. 615 0$aPharmacogenomics$xMathematical models. 615 0$aPharmacogenomics$xStatistical methods. 676 $a615.7072/7 676 $a615.70727 686 $aMAT029000$aMED045000$aMED071000$2bisacsh 702 $aCarini$b Claudio 702 $aMenon$b Sandeep M. 702 $aChang$b Mark 801 0$bFlBoTFG 801 1$bFlBoTFG 906 $aBOOK 912 $a9910806250903321 996 $aClinical and statistical considerations in personalized medicine$94098095 997 $aUNINA